Acrivon Therapeutics (ACRV) vs PDS Biotechnology (PDSB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
PDS Biotechnology (PDSB) has outperformed Acrivon Therapeutics (ACRV) over the past year, gaining 2.0% versus a loss of 0.5%. PDS Biotechnology is the larger company by market cap ($100.0 million vs $81.8 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACRV | PDSB |
|---|---|---|
| Share price | $1.91 | $1.38 |
| Market cap | $81.85M | $100.01M |
| 1-day change | +2.14% | +35.29% |
| YTD return | -22.41% | +32.47% |
| 1-year return | -0.53% | +2.00% |
| 5-year return | — | -91.73% |
| EPS (TTM) | $-1.88 | $-0.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.56 | $1.55 |
| 52-week low | $1.27 | $0.195 |
| Distance from 52-week high | -46.35% | -10.97% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +502.09% | +262.32% |
| Average volume | 356.18K | 23.24M |
| Shares outstanding | 42.85M | 72.47M |
| Employees | 74 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Acrivon Therapeutics
ACRV stock →Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.
Health Care · Biotechnology: Pharmaceutical Preparations · 74 employees
About PDS Biotechnology
PDSB stock →PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
ACRV vs PDSB FAQ
Which is bigger, Acrivon Therapeutics or PDS Biotechnology?
PDS Biotechnology (PDSB) is larger, with a market capitalization of $100.01M compared with $81.85M for Acrivon Therapeutics (ACRV).
Which stock has performed better over the past year, ACRV or PDSB?
PDSB returned +2.00% over the past 12 months, compared with -0.53% for ACRV (price return, excluding dividends). Past performance does not predict future results.
Are Acrivon Therapeutics and PDS Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.